These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: A case-control study of breast cancer and hormonal contraception in Costa Rica.
    Author: Lee NC, Rosero-Bixby L, Oberle MW, Grimaldo C, Whatley AS, Rovira EZ.
    Journal: J Natl Cancer Inst; 1987 Dec; 79(6):1247-54. PubMed ID: 2961909.
    Abstract:
    By 1981, 11% of married women in Costa Rica ages 20-49 years had used depot-medroxyprogesterone acetate (DMPA) and 58% had used oral contraceptives (OCs). Since 1977, the Costa Rican Ministry of Health has maintained a nationwide cancer registry. These circumstances provided an opportunity for a population-based, case-control study of DMPA, OCs, and breast cancer in Costa Rica. Cases were 171 women ages 25-58 years with breast cancer diagnosed between 1982 and 1984; controls were 826 women randomly chosen during a nationwide household survey. Cases and controls were interviewed with the use of a standard questionnaire covering their reproductive and contraceptive histories. Logistic regression methods were used to adjust for confounding factors. While few cases or controls had ever used DMPA, DMPA users had an elevated relative risk (RR) estimate of breast cancer of 2.6 (95% confidence limits = 1.4-4.7) compared with never users. However, no dose-response relationship was found; even the group of women who had used DMPA for less than 1 year had an elevated RR estimate (RR = 2.3; 95% confidence limits = 1.0-5.1). In contrast, OC users had no elevation in RR compared with never users (RR = 1.2; 95% confidence limits = 0.8-1.8). The results of the DMPA analysis are inconclusive. Before decisions are made on whether to continue providing this effective contraceptive method, other ongoing studies will need to confirm of refute these findings. Depot-medroxyprogesterone acetate (DMPA) is used by approximately 2 million women world-wide. In Costa Rica, by 1981 11% of the married women had used DMPA. Although no definitive link between the use of DMPA and the development of cancer has been found, the possibility has been recognized as one of the reasons for the U.S food and Drug Administration denying approval of the drug. Since 1977, the Ministry of Health in Costa Rica has sustained a national cancer registry. The accuracy of the reporting of the registry was studied by comparing a sampling of gynecologic cancer cases in the year 1983 to the national registry. In examination of the records, an elevated relative risk of breast cancer for DMPA users was found (2.6), and an elevated relative risk for women who had even used DMPA for a short period of time (2.3). The failure to interview 1/3 of the cases, differences in detection and the misclassification of DMPA use contributed cumulatively to the belief that a positive connection between breast cancer and DMPA use could otherwise be drawn. In contrast to the association found between DMPA ever use and breast cancer, no connection was found between OC use and the incidence of breast cancer. However, due to the small number of DMPA users recorded and the void of complete and accurate recorded information, the study results remain inconclusive.
    [Abstract] [Full Text] [Related] [New Search]